Therefore, if future clinical trials demonstrate anti-cancer effectiveness of combination BET and PARP inhibition treatment against neuroblastoma, this treatment strategy could be more rapidly implemented relative to other novel, untested, or unapproved agents. This evidence concerns the gene PARP1 and neuroblastoma.